| 000 | 00962 a2200253 4500 | ||
|---|---|---|---|
| 005 | 20250517211414.0 | ||
| 264 | 0 | _c20190508 | |
| 008 | 201905s 0 0 eng d | ||
| 022 | _a1527-3792 | ||
| 024 | 7 |
_a10.1016/j.juro.2018.01.031 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTaneja, Samir S | |
| 245 | 0 | 0 |
_aRe: Cabazitaxel versus Docetaxel as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. _h[electronic resource] |
| 260 |
_bThe Journal of urology _c04 2018 |
||
| 300 |
_a893-894 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Comment | ||
| 650 | 0 | 4 | _aDocetaxel |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aProstatic Neoplasms, Castration-Resistant |
| 650 | 0 | 4 | _aTaxoids |
| 773 | 0 |
_tThe Journal of urology _gvol. 199 _gno. 4 _gp. 893-894 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.juro.2018.01.031 _zAvailable from publisher's website |
| 999 |
_c28274617 _d28274617 |
||